Jun. 20 at 5:50 PM
TD Cowen Named Buy Rated
$ELVN as a Best Smidcap Idea and said "Strong Data Position '001 To Advance Care In
$B+ CML Market"
$TERN
$AAPG $TAK
$NVS PFE AZN BMY
#EHA2025
TD Cowen additionally said, "ELVN-001 is designed
to improve upon prior TKIs for CML.
At EHA ELVN-001 produced strong proof-of-concept data with a high MMR rate and benign safety profile, positioning it to become a standard therapy in this multi-
$B market.
ELVN-001 will enter pivotal development in 2026 and we project peak sales of
$3B. We think
$ELVN is undervalued for '001's potential. It is a top smidcap biotech pick."
